Compare CIVB & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVB | VALN |
|---|---|---|
| Founded | 1884 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.6M | 582.2M |
| IPO Year | 2012 | 2021 |
| Metric | CIVB | VALN |
|---|---|---|
| Price | $28.21 | $5.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $30.92 | $12.25 |
| AVG Volume (30 Days) | ★ 103.5K | 23.4K |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ 31.34 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $19,023,000.00 | N/A |
| Revenue This Year | $10.45 | N/A |
| Revenue Next Year | $4.72 | $87.65 |
| P/E Ratio | $19.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.10 | $4.75 |
| 52 Week High | $29.97 | $12.18 |
| Indicator | CIVB | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 66.50 | 37.29 |
| Support Level | $27.97 | $5.10 |
| Resistance Level | $29.31 | $5.52 |
| Average True Range (ATR) | 0.57 | 0.21 |
| MACD | 0.19 | -0.03 |
| Stochastic Oscillator | 83.07 | 5.70 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.